the sudden death of Opthea (OPT) has led the whole sector today into a sea of red, Regal, the 30% owner of Opthea, also slumps 14%.
How OPT ran into such a weird situation is beyond my apprehension, it also shows how risky and Clinical stage company could be.
On the contrary Syntara' funding structure is very healthy, multiple major shareholders most of them were recently joined, and the company is in net cash position of $20m dollars.
My only concern is Platinum (PTM)' 14% holding, sitting on a massive profit and seeing what's happened on Reral/OPT, they may choose to offload some shares to pocket the profit.
Add to My Watchlist
What is My Watchlist?
